Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Thoughts on pan can deal
View:
Post by westcoast1000 on Jun 23, 2023 7:07pm

Thoughts on pan can deal

As Ionc noted, pan can picked us to be in their trials.

Some have asked on ST what this means? Is it a lesser step forward than a big pharma partner?

My view: no, it is a much better deal for us. We give up nothing and get a free trial with the best of the best for a new standard of care. If that trial works well, we will be the SOC for the onco virus for panc. 

This agreement with pan can postpones our need to find a big pharma partner, and provides ONCY with more value to bring to a future deal. Roche should be salivating at the thought of tecntriq being the CI that goes into the pan can trials. So that is a bigger incentive for them to throw in with us with an equity deal or a buy out.

One poster who is on here and ST note that it seems likely we are getting offers but we are holding out for OS date for mBC and panc as well as more results on CRC and CAR-T before making a deal. That makes sense to me, given our results. And make no mistake, our results are more than stellar. They are amazing in panc, so far at least in terms of responses to treatment, although we have not got the OS or PFS results as yet, IIRC.

I was disappointed at the plunge in price at 11:30 today, but it is Friday, nothing goes up for ever, and there we profits to be taken for those who trade. The fact is that something like 13 mil shares changed hands. That means there are buyers out there, and lots more interest than we have seen since I have been here, roughly 10 years ago.
Comment by Noteable on Jun 23, 2023 8:12pm
From PanCan and  ONCY's recent joint announcement:   "Data presented at SITC 2022 showed a near tripling of overall response rate for pelareorep + gemcitabine + nab-paclitaxel + a PD-L1 inhibitor compared to historical control trials" PanCan seeks to fund a Phase 3 trial through its network of 20 prestigious clinical trial sites in the United States so that the above ...more  
Comment by Noteable on Jun 23, 2023 8:25pm
Watch : PanCan "Pancreatic Cancer Clinical Trials: How Research Brings new Treatments to Patients" on YouTube https://youtu.be/v-1Q0MbRYkk
Comment by Noteable on Jun 23, 2023 8:50pm
Listen to Dr. Shubham Pant of MD Anderson at the PanCan link provided who talks about immunotherapy, KRAS and turning cold tumors "hot" as pelareorep is capable of accomplishing in the treatment of pancreatic cancer.  Furthermore the Phase 3 adaptive trial design being applied in the pelareorep trial allows for fewer patient enrollment numbers due to biomarkers and next generation ...more  
Comment by Noteable on Jun 23, 2023 9:33pm
The goal of PanCAN’s Precision Promise is to accelerate drug development and bring new pancreatic cancer therapies to patients faster,” said Anne-Marie Duliege, MD, PanCAN’s Chief Medical Officer.
Comment by Noteable on Jun 23, 2023 9:43pm
https://www.fredhutch.org/en/news/center-news/2016/09/precision-promise-pancreatic-cancer-trial.html
Comment by Proboscises on Jun 23, 2023 10:12pm
Noteable, thank you for your link to the video from PanCAN.  The recent news about ONC/Y's participation in PanCAN's Precision Promise trail and the subsequent increase in share price and share volume is very gratifying. I'm very familiar with PanCAN as I recently used their services to search for clinical trials in pancreatic cancer for a close relation. They are very ...more  
Comment by Noteable on Jun 23, 2023 11:08pm
This 2021 news article briefly describes the objective of the PanCan network. https://timesofsandiego.com/tech/2021/04/15/precision-promise-trial-site-for-pancreatic-cancer-coming-to-ucsd/
Comment by itntdf on Jun 24, 2023 10:01am
hopefully will see a nice ramp up in pps during the next few months.  however, the results payoff seems like it won't come until sometime in the latter half of 2024 based on following comment in oncy's press release: Oncolytics expects to finalize the definitive agreements within the next 90 days and open the Precision Promise investigational treatment of pelareorep, checkpoint ...more  
Comment by Azzak34 on Jun 24, 2023 10:12am
Pela could be a few years away from hitting the market, unless we get accelerated approval which looks more and more likely. The premium that goes with great phase 3 results is the risk for big pharma right now. If they wait and we get more confirmation of Pelas ability the price goes up exponentially and the bidding war will push that even higher. The argument is how quickly do they acquire to ...more  
Comment by YegJeeber on Jun 24, 2023 5:17pm
That's 2024 if it's standard business as usual with the company. BP could step in at any moment and trigger a buyout. 
Comment by westcoast1000 on Jun 24, 2023 3:29pm
Thanks to Probo for this very encouraging comment. It is important to learn that ONCY will have to pay its share of the costs of the trial. However, what its share entails is an important question. I agree that the selection of the CI to be included in that trial is a fundamental piece of puzzle for ONCY. If is it Roche, one could expect they become our partner leading to a buyout. Another ...more  
Comment by westcoast1000 on Jun 24, 2023 4:09pm
My guess is that PanCan learned more about pela from the conference presentation earlier in June. The investigator was on the featured panel. That surely got us some attention and likely helped sway the BOD of PanCan to include pela in their trial
Comment by inthno on Jun 24, 2023 6:52pm
A lot of good comments and thoughts for sure and most likely the best PR we have had overall in years as this sets the stage for everything that onc has worked for. Now the big question and really should be no question at all in regards to the ci that should be included in the precision trial....There would be no way that onc would or should take a chance with a different ci knowing that it was ...more  
Comment by newcoin on Aug 20, 2023 9:56am
inthno, are you still thinking the same way as in this June post? Things change quickly and the summer is slow. Nobody knows. I just want to know if you're as positive as you were a few months ago. I really value your opinion.  
Comment by inthno on Aug 20, 2023 11:36am
Hello Newcoin and always good to hear from you, As always comments will be subjective and everyone has their view and I can understand that. All the shareholdes are outsiders and have no real idea of what is going on other than the dd that we get from our searches and from others on the boards that do quite an amazing job. My take only,,,,,I will start with mbc IND 213 was outstanding and set the ...more  
Comment by newcoin on Aug 20, 2023 1:35pm
inthno, thanks for sharing your thoughts. I'm excited about this fall and the NRs that will come out. We are so close now after all these years. It's great to be able to jump back in at a reasonable s/p. I watch daily and look to add on any dips. As mentioned, I will have a full position by the end of month. GLTA
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities